A retrospective to determine impact of histological variants on survival and response to treatment with pembrolizumab in patients with chemoresistant urothelial cancer
Latest Information Update: 21 Jun 2022
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Carcinoma; Squamous cell cancer; Urogenital cancer
- Focus Therapeutic Use
- 16 May 2022 Results presented at the 117th Annual Meeting of the American Urological Association
- 18 Jun 2021 New trial record
- 10 Jun 2021 Results published in the BJU International